



## **ASX RELEASE**

### **Volpara Quarterly Results and Investor Webcast Notification**

Wellington, NZ, 19th January 2021: Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX: VHT), a health technology software company whose integrated breast care platform assists in the delivery of personalised patient care, advises it will release its Appendix 4C – Quarterly Cash Flow Statement for the period ended 31<sup>st</sup> December 2020, on Thursday 28<sup>th</sup> January 2021.

Investors are invited to join a webcast hosted by Group CEO Dr Ralph Highnam, Volpara Health CEO Katherine Singson, and CFO Craig Hadfield, on Thursday 28<sup>th</sup> January 2021 at 9:00am Australian Eastern Daylight Time (AEDT).

To register for the webcast, please follow this link:

[https://us02web.zoom.us/webinar/register/WN\\_L0PH7y7MSqePluiLaVbZDg](https://us02web.zoom.us/webinar/register/WN_L0PH7y7MSqePluiLaVbZDg)

*Registered participants will receive a confirmation email containing the Zoom access link and alternative phone dial-ins.*

**ENDS**

### **Authorisation and Additional Information**

This announcement was authorised by the Group CEO Dr Ralph Highnam.

#### **For further information, please contact:**

Ralph Highnam, CEO  
Volpara Health Technologies  
[ralph.highnam@volparahealth.com](mailto:ralph.highnam@volparahealth.com)  
t: +64 21 149 0541

Trevor Chappell  
WE Communications  
[WE-AUVolpara@we-worldwide.com](mailto:WE-AUVolpara@we-worldwide.com)  
t: +61 407 933 437

### **About Volpara Health Technologies Limited (ASX: VHT)**

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020. VHT is based in Wellington, New Zealand.

For more information, visit [www.volparahealth.com](http://www.volparahealth.com)